About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID 		Ptpn11tm1Ckq
targeted mutation 1, Cheng-Kui Qu
MGI:5295460
Summary 6 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
ht1
 		Ptpn11tm1Ckq/Ptpn11+ involves: 129S6/SvEvTac * C57BL/6J MGI:5295463
cn2
 		Cd19tm1(cre)Cgn/Cd19+
Ptpn11tm1Ckq/Ptpn11+ 		involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J MGI:5295466
cn3
 		Ptpn11tm1Ckq/Ptpn11+
Lyz2tm1(cre)Ifo/Lyz2+ 		involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J MGI:5295468
cn4
 		Hprt1tm1(CAG-cre)Mnn/Hprt1+
Ptpn11tm1Ckq/Ptpn11+ 		involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6J MGI:5295464
cn5
 		Ptpn11tm1Ckq/Ptpn11+
Tg(Mx1-cre)1Cgn/0 		involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * CBA MGI:5295465
cn6
 		Ptpn11tm1Ckq/Ptpn11+
Tg(Lck-cre)1Cwi/0 		involves: 129S6/SvEvTac * C57BL/6J MGI:5295469


Genotype
MGI:5295463
ht1
Allelic
Composition		 Ptpn11tm1Ckq/Ptpn11+
Genetic
Background		 involves: 129S6/SvEvTac * C57BL/6J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ptpn11tm1Ckq mutation (0 available); any Ptpn11 mutation (46 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
normal phenotype
no abnormal phenotype detected ( J:177285 )
• mice show no abnormalities




Genotype
MGI:5295466
cn2
Allelic
Composition		 Cd19tm1(cre)Cgn/Cd19+
Ptpn11tm1Ckq/Ptpn11+
Genetic
Background		 involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (11 available); any Cd19 mutation (60 available)
Ptpn11tm1Ckq mutation (0 available); any Ptpn11 mutation (46 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging

neoplasm
increased acute lymphoblastic leukemia incidence ( J:177285 )
• B cell lymphoblastic leukemia/lymphoma in 4 of 9 mice
increased B cell derived lymphoma incidence ( J:177285 )
• B cell lymphoblastic leukemia/lymphoma in 4 of 9 mice




Genotype
MGI:5295468
cn3
Allelic
Composition		 Ptpn11tm1Ckq/Ptpn11+
Lyz2tm1(cre)Ifo/Lyz2+
Genetic
Background		 involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Lyz2tm1(cre)Ifo mutation (14 available); any Lyz2 mutation (40 available)
Ptpn11tm1Ckq mutation (0 available); any Ptpn11 mutation (46 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging

neoplasm
increased acute promyelocytic leukemia incidence ( J:177285 )
• acute myeloid leukemia in 4 of 10 mice

immune system
myeloid hyperplasia ( J:177285 )
• all mice develop myeloproliferative disease with enhanced myeloid cell proliferation and differentiation
• 2 of 10 mice develop accelerated myeloproliferative disease

hematopoietic system
myeloid hyperplasia ( J:177285 )
• all mice develop myeloproliferative disease with enhanced myeloid cell proliferation and differentiation
• 2 of 10 mice develop accelerated myeloproliferative disease




Genotype
MGI:5295464
cn4
Allelic
Composition		 Hprt1tm1(CAG-cre)Mnn/Hprt1+
Ptpn11tm1Ckq/Ptpn11+
Genetic
Background		 involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Hprt1tm1(CAG-cre)Mnn mutation (1 available); any Hprt1 mutation (1279 available)
Ptpn11tm1Ckq mutation (0 available); any Ptpn11 mutation (46 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype

Embryonic lethality in Ptpn11tm1Ckq/Ptpn11+ Hprt1tm1(CAG-cre)Mnn/Hprt1+ mice

mortality/aging

embryo

cardiovascular system

craniofacial

growth/size/body
embryonic growth retardation ( J:177285 )
• at E9.5




Genotype
MGI:5295465
cn5
Allelic
Composition		 Ptpn11tm1Ckq/Ptpn11+
Tg(Mx1-cre)1Cgn/0
Genetic
Background		 involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * CBA
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ptpn11tm1Ckq mutation (0 available); any Ptpn11 mutation (46 available)
Tg(Mx1-cre)1Cgn mutation (7 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype

Increased spleen weight in Ptpn11tm1Ckq/Ptpn11+ Tg(Mx1-cre)1Cgn/0 mice

mortality/aging
premature death ( J:177285 )
• by 56 weeks due to leukemia in pIpC-treated mice

hematopoietic system
increased lymphoblastic lymphoma incidence ( J:177285 )
• T cell lymphoblastic leukemia/lymphoma in 9 of 27 pIpC-treated mice
enlarged spleen ( J:177285 )
• in pIpC-treated mice
increased spleen weight ( J:177285 )
• in pIpC-treated mice
arrested B cell differentiation ( J:177285 )
• around the pro-B stage in pIpC-treated mice
myeloid hyperplasia ( J:177285 )
• all pIpC-treated mice develop myeloproliferative disease (MPD)
• Mac-1+/Gr-1+ mature myeloid cells are increased
• 5 of 27 pIpC-treated mice exhibit accelerated MPD
extramedullary hematopoiesis ( J:177285 )
• hyperproliferation in the liver and spleen in pIpC-treated mice
anemia ( J:177285 )
• progressive in pIpC-treated mice
abnormal bone marrow cell morphology/development ( J:177285 )
• pIpC-treated mice exhibit decreased common myeloid progenitors, granulocyte macrophage progenitors, and megakaryocyte erythroid progenitors compared with wild-type mice
• however, common lymphoid progenitor numbers are normal
increased leukocyte cell number ( J:177285 )
• extremely high after 32 weeks with leukemia infiltration in nonhematopoietic organs of pIpC-treated mice
increased neutrophil cell number ( J:177285 )
• in pIpC-treated mice
decreased hematopoietic stem cell number ( J:177285 )
• 3-fold in the bone marrow in pIpC-treated mice
increased hematopoietic stem cell number ( J:177285 )
• in the spleen of pIpC-treated mice
abnormal hematopoietic stem cell physiology ( J:177285 )
• hematopoietic stem cells are hyperactivated in pIpC-treated mice
• hematopoietic stem cell quiescent in pIpC-treated mice is decreased 2-fold while the S and G2/M phase were doubled compared to in wild-type mice
• apoptosis of hematopoietic stem cells in pIpC-treated mice is decreased compared to in wild-type mice

neoplasm
increased lymphoblastic lymphoma incidence ( J:177285 )
• T cell lymphoblastic leukemia/lymphoma in 9 of 27 pIpC-treated mice
increased leukemia incidence ( J:177285 )
• after 12 to 32 weeks of chronic myeloproliferative disease in pIpC-treated mice
increased acute lymphoblastic leukemia incidence ( J:177285 )
• B and T cell lymphoblastic leukemia/lymphoma in pIpC-treated mice
increased acute promyelocytic leukemia incidence ( J:177285 )
• acute myeloid leukemia in 6 of 27 pIpC-treated mice
increased B cell derived lymphoma incidence ( J:177285 )
• B cell lymphoblastic leukemia/lymphoma in 2 of 27 pIpC-treated mice

cellular
aneuploidy ( J:177285 )
• in bone marrow cells and splenocytes from pIpC-treated mice
chromosomal instability ( J:177285 )
• in pIpC-treated mice due to centrosome amplification

liver/biliary system
enlarged liver ( J:177285 )
• in pIpC-treated mice

immune system
increased lymphoblastic lymphoma incidence ( J:177285 )
• T cell lymphoblastic leukemia/lymphoma in 9 of 27 pIpC-treated mice
enlarged spleen ( J:177285 )
• in pIpC-treated mice
increased spleen weight ( J:177285 )
• in pIpC-treated mice
arrested B cell differentiation ( J:177285 )
• around the pro-B stage in pIpC-treated mice
myeloid hyperplasia ( J:177285 )
• all pIpC-treated mice develop myeloproliferative disease (MPD)
• Mac-1+/Gr-1+ mature myeloid cells are increased
• 5 of 27 pIpC-treated mice exhibit accelerated MPD
increased leukocyte cell number ( J:177285 )
• extremely high after 32 weeks with leukemia infiltration in nonhematopoietic organs of pIpC-treated mice
increased neutrophil cell number ( J:177285 )
• in pIpC-treated mice

endocrine/exocrine glands
increased lymphoblastic lymphoma incidence ( J:177285 )
• T cell lymphoblastic leukemia/lymphoma in 9 of 27 pIpC-treated mice

growth/size/body
enlarged liver ( J:177285 )
• in pIpC-treated mice
enlarged spleen ( J:177285 )
• in pIpC-treated mice
increased spleen weight ( J:177285 )
• in pIpC-treated mice




Genotype
MGI:5295469
cn6
Allelic
Composition		 Ptpn11tm1Ckq/Ptpn11+
Tg(Lck-cre)1Cwi/0
Genetic
Background		 involves: 129S6/SvEvTac * C57BL/6J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ptpn11tm1Ckq mutation (0 available); any Ptpn11 mutation (46 available)
Tg(Lck-cre)1Cwi mutation (3 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
endocrine/exocrine glands
increased lymphoblastic lymphoma incidence ( J:177285 )
• T cell lymphoblastic leukemia/lymphoma in 8 of 15 mice

mortality/aging

neoplasm
increased lymphoblastic lymphoma incidence ( J:177285 )
• T cell lymphoblastic leukemia/lymphoma in 8 of 15 mice
increased acute lymphoblastic leukemia incidence ( J:177285 )
• T cell lymphoblastic leukemia/lymphoma in 8 of 15 mice

immune system
immune system phenotype ( J:177285 )
N
• T and B cell development is normal
increased lymphoblastic lymphoma incidence ( J:177285 )
• T cell lymphoblastic leukemia/lymphoma in 8 of 15 mice

hematopoietic system
increased lymphoblastic lymphoma incidence ( J:177285 )
• T cell lymphoblastic leukemia/lymphoma in 8 of 15 mice




Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
11/19/2024
MGI 6.24 		The Jackson Laboratory